Diseases / Retinitis Pigmentosa
Retinitis Pigmentosa Clinical Trials
DiseaseRetinitis pigmentosa is a group of rare inherited retinal diseases that progressively damage photoreceptor cells and lead to vision loss. Symptoms often begin with night blindness and then progressive peripheral field loss. Over time, vision can narrow substantially and may progress to severe impairment.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow Retinitis Pigmentosa
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa NCT06628947 | Phase 2 | Recruiting | Kiora Pharmaceuticals, Inc. | Started 2025-08 |
Recently started
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| A Study of the Safety and Preliminary Efficacy of UGX202 in Patients With Advanced Retinitis Pigmentosa NCT07847723 | Phase 1 | Not yet recruiting | Suzhou UgeneX Therapeutics Co., Ltd. | Started 2026-09 |
| Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa NCT07774975 | Phase 1 | Not yet recruiting | Kyushu University | Started 2026-09 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome NCT07710196 | Phase 3 | Not yet recruiting | Nacuity Pharmaceuticals, Inc. | Started 2026-08 |
| 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients NCT07509229 | Phase 1/2 | Enrolling by invitation | Sheba Medical Center | Started 2026-07 |
| Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment NCT07341763 | Phase n/a | Recruiting | University of Waterloo | Started 2026-07 |
Results recently posted
| Trial | Phase | Status | Sponsor | Results posted |
|---|---|---|---|---|
| A Study in Subjects With Retinitis Pigmentosa NCT05392179 | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | Results posted 2026-04-23 |
| Sildenafil for Treatment of Choroidal Ischemia NCT04356716 | Phase 2 | Completed | Columbia University | Results posted 2025-07-04 |
| A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa NCT00447980 | Phase 2 | Completed | Neurotech Pharmaceuticals | Results posted 2025-05-01 |
| Environmental Localization Mapping and Guidance for Visual Prosthesis Users NCT04359108 | Phase n/a | Completed | Johns Hopkins University | Results posted 2025-03-10 |
| Advancing Understanding of Transportation Options NCT04141891 | Phase n/a | Completed | University of Colorado, Denver | Results posted 2025-02-21 |
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | 1 | — | — | — | — | — | — | 4 | — | 6 |
| Phase 1 | 4 | 2 | — | 5 | 12 | 1 | — | — | 1 | — | 25 |
| Phase 1/2 | 9 | 2 | 1 | 8 | 13 | 4 | — | — | 4 | — | 41 |
| Phase 2 | 1 | 1 | — | 2 | 16 | 1 | — | — | 4 | — | 25 |
| Phase 2/3 | — | 1 | — | — | — | 2 | — | — | 1 | — | 4 |
| Phase 3 | — | 3 | — | 4 | 6 | 1 | — | — | — | — | 14 |
| Phase 4 | — | — | — | — | 1 | — | — | — | — | — | 1 |
| Not applicable | 8 | 2 | 1 | 2 | 33 | 3 | 5 | — | 9 | — | 63 |
| Unknown | 16 | 4 | 3 | 7 | 34 | 6 | 1 | 1 | 14 | 1 | 87 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Retinitis Pigmentosa | 6 | 25 | 41 | 25 | 4 | 14 | 1 | 63 | 87 | 266 |
| Retinal Degeneration | 1 | 3 | 7 | 2 | — | — | — | 6 | 14 | 33 |
| Retinal Diseases | — | 3 | 6 | 8 | 2 | 1 | — | 4 | 9 | 33 |
| Eye Diseases | — | 2 | 8 | 5 | 2 | — | — | 4 | 7 | 28 |
| Usher Syndromes | — | — | 4 | 4 | 2 | 3 | — | 1 | 12 | 26 |
| Macular Degeneration | — | 3 | 1 | 1 | — | — | — | 9 | 11 | 25 |
| Retinal Dystrophies | — | 1 | 4 | 1 | — | — | — | 3 | 10 | 19 |
| Cone-Rod Dystrophies | — | — | 5 | 1 | — | — | — | 8 | 4 | 18 |
| Eye Diseases, Hereditary | — | — | 4 | 4 | 2 | — | — | 1 | 5 | 16 |
| Vision Disorders | — | — | 3 | 3 | 2 | — | — | 6 | 2 | 16 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Eye Institute (NEI) | 13 | 2 |
| 2 | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | 9 | 0 |
| 3 | Johns Hopkins University | 8 | 1 |
| 4 | Second Sight Medical Products | 6 | 0 |
| 5 | Sheba Medical Center | 6 | 0 |
| 6 | Ankara Universitesi Teknokent | 5 | 2 |
| 7 | Laboratoires Thea | 5 | 2 |
| 8 | Nanoscope Therapeutics Inc. | 5 | 0 |
| 9 | Okuvision GmbH | 5 | 0 |
| 10 | Retina Implant AG | 5 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | salicylhydroxamic acid | 5 |
| 2 | Intravitreal Injections | 4 |
| 3 | Ciliary Neurotrophic Factor | 3 |
| 4 | Docosahexaenoic Acids | 3 |
| 5 | Minocycline | 3 |
| 6 | retinol acetate | 3 |
| 7 | Vitamin A | 3 |
| 8 | Acetylcysteine | 2 |
| 9 | cenegermin | 2 |
| 10 | Culture Media, Conditioned | 2 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT03328130 Terminated | Terminated | lack of financing | 2025-06-30 |
| NCT04558983 Terminated | Terminated | The study stopped because patients dropped out of the study to participate in the interventional trials. With interventional trials present there is very little interest in participating in a Natural Histoy study. | 2024-12-20 |
| NCT04120883 Terminated | Terminated | Unable to recruit additional participants after multiple extensions to planned enrollment period. | 2024-08-05 |
| NCT05392751 Terminated | Terminated | Study terminated by the Sponsor. All study participants completed at least 12 months of safety follow-up instead of 24 mo. The reason for earlier termination was due to a corporate decision; not any safety concerns of EA-2353. | 2024-04-24 |
| NCT04295304 Terminated | Terminated | Lack of funds | 2023-03-12 |
| NCT05085964 Terminated | Terminated | The sponsor decided to terminate the study early | 2022-10-18 |
| NCT05158296 Terminated | Terminated | Business decision | 2022-10-12 |
| NCT05176717 Terminated | Terminated | Business decision | 2022-08-02 |
| NCT01490827 Terminated | Terminated | Sponsor discontinued the Argus II product | 2020-03-31 |
| NCT01860092 Terminated | Terminated | Manufacturing ceased for all Argus II and Argus 2s devices (FDA notified of and subsequently approved discontinuation of post approval study in Oct 2021) | 2020-03-31 |
Evidence
- Results reported
- 30.4%35 of 115 completed
- Published
- 29.6%34 of 115 completed
- Primary endpoint met
- 57.8%26 of 45 analyses
- Median months to report
- 17
Documents disclosed
Trial profile
- Median enrollment
- 30
- Median duration
- 36months
- Countries
- 43
- Study sites
- 571
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 21
- Phase 1
- 15
- Phase 1/2
- 19
- Phase 2
- 45
- Phase 2/3
- 19
- Phase 3
- 80
- Phase 4
- 40
- Not applicable
- 21
- Unknown
- 52
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Paris | France | 29 |
| 2 | Dallas | United States | 26 |
| 3 | Tübingen | Germany | 21 |
| 4 | Baltimore | United States | 20 |
| 5 | Boston | United States | 20 |
| 6 | London | United Kingdom | 20 |
| 7 | Portland | United States | 19 |
| 8 | Ann Arbor | United States | 18 |
| 9 | Miami | United States | 16 |
| 10 | Philadelphia | United States | 14 |